However, our results did not reveal any association between the lipid-lowering drugs NPC1L1, CETP, APOB, APOC3, or ANGPTL3, and the risk of sleep apnea syndrome (Table S7, Supplemental Digital Content, http://links.lww.com/MD/N781). Here, CETP is linked to sleep apnea syndrome.